Listen Top Shows Blog

CRS-207: Using a Modified Listeria Virus to Fight Mesothelioma

CRS-207: Using a Modified Listeria Virus to Fight Mesothelioma

Update: 2014-09-15

Share

Description

The focus of the interview is Aduro BioTech’s experimental therapy for malignant pleural mesothelioma, known as CRS-207. CRS-207 is a weakened form of the Listeria bacteria modified to reduce its ability to cause infections, but still able to stimulate the immune system.

Comments

In Channel

Meet the Mesothelioma Experts: Advocacy Edition

Meet the Mesothelioma Experts: Advocacy Edition

2018-03-0246:03

An interview with Aduro Biotech

An interview with Aduro Biotech

2017-11-0943:14

"Targeting the Immune System" with Dr. Dan Sterman of NYU

"Targeting the Immune System" with Dr. Dan Sterman of NYU

2017-07-1736:35

Meet Marjorie Zauderer, MD, of Memorial Sloan Kettering Cancer Center

Meet Marjorie Zauderer, MD, of Memorial Sloan Kettering Cancer Center

2016-11-0745:34

Current Trends in Mesothelioma Surgery and Research: The International Mesothelioma Program at Brigham and Women's Hospital,

Current Trends in Mesothelioma Surgery and Research: The International Mesothelioma Program at Brigham and Women's Hospital,

2016-04-1239:44

2015 Grant Recipient Interviews - Part 1

2015 Grant Recipient Interviews - Part 1

2016-02-1853:17

Focus on Centers of Excellence: Penn Medicine with Dr. Evan Alley and Dr. Charles Simone

Focus on Centers of Excellence: Penn Medicine with Dr. Evan Alley and Dr. Charles Simone

2015-05-1556:29

Focus on Mesothelioma Centers of Excellence: Hedy Lee Kindler, MD, University of Chicago Medicine

Focus on Mesothelioma Centers of Excellence: Hedy Lee Kindler, MD, University of Chicago Medicine

2015-04-2749:04

CRS-207: Using a Modified Listeria Virus to Fight Mesothelioma

CRS-207: Using a Modified Listeria Virus to Fight Mesothelioma

2014-09-1527:38

PD-L1 Inhibitors: Interview with Dr. Evan Alley of UPENN, about a new mesothelioma clinical trial

PD-L1 Inhibitors: Interview with Dr. Evan Alley of UPENN, about a new mesothelioma clinical trial

2014-05-1935:15

Meet the Mesothelioma Experts: Defactinib, a New Investigational Agent for Mesothelioma

Meet the Mesothelioma Experts: Defactinib, a New Investigational Agent for Mesothelioma

2014-04-0953:38

Focused Discussion of a New Clinical Trial: GL-ONC1 - Dr. Valerie Rusch

Focused Discussion of a New Clinical Trial: GL-ONC1 - Dr. Valerie Rusch

2014-03-2722:39

Dr. Joseph Friedberg - UPENN: New Frontiers in Surgery for Mesothelioma

Dr. Joseph Friedberg - UPENN: New Frontiers in Surgery for Mesothelioma

2014-01-3148:16

Melissa Culligan, RN - Designing Clinical Trials for Mesothelioma

Melissa Culligan, RN - Designing Clinical Trials for Mesothelioma

2013-06-0522:34

Intrapleural Measles Virus Therapy in Patients With Malignant Pleural Mesothelioma

Intrapleural Measles Virus Therapy in Patients With Malignant Pleural Mesothelioma

2012-10-2454:37

"NGR-hTTNF: A New Multi-Center Drug Trial for Pleural Mesothelioma" with Dr. Julie Brahmer, MD of Johns Hopkins

"NGR-hTTNF: A New Multi-Center Drug Trial for Pleural Mesothelioma" with Dr. Julie Brahmer, MD of Johns Hopkins

2012-06-1427:35

Mesothelin: A New Target for Immunotherapy - Dr. Raffit Hassan

Mesothelin: A New Target for Immunotherapy - Dr. Raffit Hassan

2012-05-2435:07

Recent Advances in Mesothelioma Gene Therapy

Recent Advances in Mesothelioma Gene Therapy

2012-03-0751:44

00:00

00:00

x

CRS-207: Using a Modified Listeria Virus to Fight Mesothelioma

CRS-207: Using a Modified Listeria Virus to Fight Mesothelioma

Cure Mesothelioma